Bristol-Myers (BMY) Shares Continuing Lower as Morgan Stanley Cuts to Equalweight
Get Alerts BMY Hot Sheet
Price: $63.83 -1.27%
Rating Summary:
12 Buy, 22 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
12 Buy, 22 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Shares of Bristol-Myers Squibb Co. (NYSE: BMY) are dipping rather sharply Thursday morning following a just-released downgrade from Morgan Stanley. The stock last traded at $33 even, down nearly 2.2 percent from Wednesday's close.
The firm now rates Bristol-Myers shares an Equalweight, down from Overweight previously.
For an analyst ratings summary and ratings history on Bristol-Myers Squibb Co. click here. For more ratings news on Bristol-Myers Squibb Co. click here.
The firm now rates Bristol-Myers shares an Equalweight, down from Overweight previously.
For an analyst ratings summary and ratings history on Bristol-Myers Squibb Co. click here. For more ratings news on Bristol-Myers Squibb Co. click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA grants accelerated approval to Bristol Myers Squibb's Zenbexus
- JPMorgan Downgrades KinderCare Learning Companies (KLC) to Underweight
- Bristol Myers Squibb plans $2.3B manufacturing campus in Houston
Create E-mail Alert Related Categories
DowngradesRelated Entities
Morgan StanleySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share